Polyrizon Submits Pre-Request for FDA Designation for PL-16 Viral Blocker

Reuters12-19
Polyrizon Submits Pre-Request for FDA Designation for PL-16 Viral Blocker

Polyrizon Ltd., a pre-clinical-stage biotechnology company, has submitted a Pre-Request for Designation (Pre-RFD) to the U.S. Food and Drug Administration (FDA) for its PL-16 Viral Blocker. This non-pharmacological intranasal product is designed to reduce exposure to airborne respiratory viruses, such as influenza and cold viruses, by forming a temporary physical barrier on the nasal mucosa. The Pre-RFD submission initiates a formal regulatory dialogue with the FDA to determine the appropriate regulatory pathway for PL-16 based on its physical mode of action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605098-en) on December 19, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment